x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Don"t Just Read the Abstract

Want to stay up-to-date on the very latest developments in non-malignant haematology? Don"t have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi

health & fitness

All Episodes

1:02:56

BSH President Dr Sue Pavord: An Interview

Don"t Just Read the Abstract ·

2025/10/29

In this episode, Pip and Rich chat to Dr Sue Pavord, current President of the British Society of Haematology. Over the last 18 months Dr Pavord has led from the front with serious work on defining liaison haematology, paving the way for this to be formally incorporated into haematologists' job plans. They also discuss Dr Pavord's pivotal role as a clinical leader in the UK's response to Vaccine Induced Immune Thrombosis with Thrombocytopenia (VITT). Her insight into medicine, politics, and strategy

en

4:08

DJRTA Newsletter #2

Don"t Just Read the Abstract ·

2025/10/22

Pip and Rich preview their second Don't Just Read the Abstract newsletter. This week, the newsletter focuses on the work that the British Society for Haematology have being doing on workforce planning and liaison haematology in particular. If you would like to read Dr Sue Pavord's BSH message you can find it here.The paper we mention: Ransome et al. Defining ‘liaison haematology’ in the UK: a modified Delphi study. BMJ Open. 2025. To receive the newsletter, go to www.dontjustreadtheabstract.com and

en

1:05:35

Intervention for Intermediate-High Risk PE

Don"t Just Read the Abstract ·

2025/10/15

When Dr Peter Douglas listened to our episode on the PEERLESS trial (S1, Ep12), he began to develop a funny sensation in his chest.Emailing us he wrote:"Your commentary on this paper lead me to develop the signs and symptoms of submassive PE. I am an interventional radiologist who has spent the last 3-4 years setting up a PERT and catheter based therapy service for PE and would love to speak to you further about this. In a nutshell... you missed the point. But the point is not something the authors

en

4:15

Introducing the DJRTA Newsletter

Don"t Just Read the Abstract ·

2025/10/07

In this 5 minute episode, Pip and Rich introduce the brand new Don't Just Read the Abstract Newsletter, a twice monthly update on all things medical haematology. Covering latest developments and publications in haemostasis, thrombosis, transfusion, immunohaematology, and red cell haematology, the newsletter will keep you up-to-date on what matters to patients.Sign up at www.dontjustreadtheabstract.com. Hosted on Acast. See acast.com/privacy for more information.

en

1:12:33

HI-PRO: Apixaban for Extended Treatment of Provoked...

Don"t Just Read the Abstract ·

2025/09/30

On this episode, Pip and Rich discuss Piazza et al. Apixaban for Extended Treatment of Provoked Venous Thromboembolism, published in the New England Journal of Medicine in August 2025. This trial randomised 600 patients with VTE provoked by a transient risk factor but who also had at least one enduring risk factor, after completing 3 months of anticoagulation, to receive either apixaban 2.5 mg twice daily or placebo for 12 months. Extended apixaban reduced recurrent VTE from 10.0% to 1.3% (HR 0.13,

en

1:07:39

API-CAT: Author interview with Prof. Isabelle Mahé

Don"t Just Read the Abstract ·

2025/09/15

Prof. Isabelle Mahé is a cardiologist, triallist, and Professor of Internal Medicine Paris Cité University, France. She recently led the API-CAT study, a randomised controlled trial of apixaban 2.5 mg BD vs 5 mg BD for treatment of patients with cancer associated venous thromboembolism after 6 months of therapy. Pip and Rich discussed API-CAT in detail in episode 20 and now seize the opportunity to speak to an international expert and leader in the field about the art of the trial. API-CAT was

en

59:40

API-CAT: Extended Reduced-Dose Apixaban for...

Don"t Just Read the Abstract ·

2025/07/21

In this episode, Pip and Rich go beyond the abstract of the API-CAT study, a randomised controlled trial of apixaban 5 mg BD vs 2.5 mg BD in patients with cancer-associated PE or DVT who have completed 6 months of anticoagulation. The study reported non-inferiority for low-dose apixaban in terms of VTE recurrence with a reduction in clinical relevant bleeding. This is an interesting, practice-changing study but there is plenty of nuance and a lot to discuss. Don't miss this one! Hosted on Acast

en

52:35

LUNA3: Rilzabrutinib for ITP

Don"t Just Read the Abstract ·

2025/07/06

In this episode of Don't Just Read the Abstract, Pip and Rich critically appraise LUNA3, a 2:1 randomised controlled trial of rilzabrutinib vs placebo in adults with persistent or chronic ITP. This is the first therapy to prove an improvement in fatigue in ITP, but does it live up to expectation? Listen to this episode and find out.Do you like our show? Please share with friends, colleagues, and the wider world on social media.ReferencesKuter et al. 2025 - LUNA-3 TrialQuality of Life Outcomes in

en

55:15

Haematology in The Gambia with Dr Megan Kell

Don"t Just Read the Abstract ·

2025/06/12

Dr Megan Kell is a UK haematologist, currently practising in Sheffield. She is the Chair of the British Society of Haematology's Global Haematology Specialist Interest Group and has a long standing interest in Global Health. She recently returned from over two years working as one of only two haematologists in the small, west African nation of The Gambia. This is an eye-opening interview which makes you realise what we take for granted. There are some great stories in here about how to improvise,

en

1:03:21

Efanesoctocog alfa for severe haemophilia A: expert...

Don"t Just Read the Abstract ·

2025/05/30

On this episode, Pip interviews Dr Susie Shapiro, consultant haematologist in Oxford, UK, about the recent UK approval of efanesoctocog alfa, a very long half-life factor VIII product for severe haemophilia. To find out more about this treatment, listen to our first episode on the subject (Efanesoctocog alfa - a very long half life factor VIII) where we discuss the evidence. Hosted on Acast. See acast.com/privacy for more information.

en

48:16

Efanesoctocog alfa - a very long half life factor VIII

Don"t Just Read the Abstract ·

2025/05/16

On this episode, Rich and Pip discuss the very long half life factor VIII product efanesoctocog alfa (trade names Altuvoct and Altuviiio). They discuss the 2023 NEJM paper that has recently prompted its approval for use in the UK NHS. This is the first of two episodes on this subject. Hosted on Acast. See acast.com/privacy for more information.

en

23:55

BSH Day 2

Don"t Just Read the Abstract ·

2025/04/28

Pip and Rich discuss the happenings from day 2 of the British Society of Haematology Annual Scientific Meeting Hosted on Acast. See acast.com/privacy for more information.

en

31:40

BSH Day 1

Don"t Just Read the Abstract ·

2025/04/27

On this show, Pip and Rich discuss the first day of BSH, focusing on medical haematology. Hosted on Acast. See acast.com/privacy for more information.

en

52:43

Preview of BSH 2025: a focus on non-malignant...

Don"t Just Read the Abstract ·

2025/04/18

In this episode, Rich and Pip review the programme for BSH 2025 and discuss the non-malignant haematology sessions not to miss. This is your go to guide for Glasgow 2025 beginning on 27th April. Hosted on Acast. See acast.com/privacy for more information.

en

1:05:31

PEERLESS - Management of Acute Intermediate-Risk PE

Don"t Just Read the Abstract ·

2025/04/04

On this episode, Pip and Rich discuss Jaber et al. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial. PEERLESS was a trial that enrolled patients with intermediate-risk (sub-massive) PE and randomised them to either large-bore mechanical thrombectomy or catheter directed thrombolysis. The headline finding from PEERLESS is that mechanical thrombectomy is

en

1:02:44

AI powered ultrasound for DVT - an interview with CEO...

Don"t Just Read the Abstract ·

2025/03/21

On this episode, Pip and Rich chat to Fouad Al Noor, CEO of ThinkSono. ThinkSono have developed an AI-powered handheld scanning tool for DVT that enables anyone to perform a diagnostic quality ultrasound scan for the diagnosis of DVT. The images are then reviewed by a radiologist, providing a rapid answer for most patients. The tool is entering use within the NHS and in this podcast, Pip and Rich discuss the story and the evidence behind ThinkSono as well as the challenges and opportunities that the

en

51:15

Iptacopan for PNH

Don"t Just Read the Abstract ·

2025/03/07

In this episode, Rich and Pip discuss de Latour et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. NEJM 2024. Iptacopan is a proximal complement inhibitor and the first oral treatment for paroxysmal nocturnal haemoglobinuria. The study randomised patients to either continuation of a C5 inhibitor or switch to ictacopan and found that a significant proportion of patients achieved hemoglobin levels of 120 g/L or higher without the need for transfusions. The treatment was

en

1:06:42

Plasma exchange free treatment of TTP: Author Discussion

Don"t Just Read the Abstract ·

2025/02/21

In this episode, Pip and Rich discuss plasma exchange free treatment of thrombotic thrombocytopenic purpura with Dr Lucas Kuhne and Professor Paul Brinkoetter, authors of a recent study in Blood: Kühne et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.The study is an observational, retrospective study reporting outcomes of patients with TTP who were treated without plasma exchange, which is currently considered the standard of care. The advent of a

en

56:14

Plasma exchange free treatment of TTP

Don"t Just Read the Abstract ·

2025/01/31

In this episode, Rich and Pip discuss a paper a German/Austrian study published in Blood: Kühne et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.The study is an observational, retrospective study reporting outcomes of patients with TTP who were treated without plasma exchange, which is currently considered the standard of care. The advent of a novel nanobody against vWF called caplacizumab, that targets and prevents catastrophic thrombosis that is

en

1:09:59

7. Exa-cel for severe sickle cell disease

Don"t Just Read the Abstract ·

2024/11/12

In this episode, Rich and Pip discuss gene therapy for sickle cell disease, focusing on Frangoul et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease, NEJM 2024. Hosted on Acast. See acast.com/privacy for more information.

en

26 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown